Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosuvastatin/choline fenofibrate

Drug Profile

Rosuvastatin/choline fenofibrate

Alternative Names: ABT-143; ABT-335/rosuvastatin; Certriad; choline-fenofibrate/rosuvastatin; Rosuvastatin/ABT-335; Rosuvastatin/fenofibric acid delayed release

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories; AstraZeneca
  • Class Antihyperlipidaemics; Fibric acid derivatives; Fluorobenzenes; Propionates; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 22 Dec 2010 Discontinued - Preregistration for Hyperlipidaemia in USA (PO)
  • 30 Mar 2010 AstraZeneca & Abbott receive complete response letter from the FDA for rosuvastatin/choline fenofibrate in Hyperlipidaemia
  • 19 Jun 2009 Post-hoc efficacy data from two phase III trials in Dyslipidaemia presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top